Increased risk of myopathy & rhabdomyolysis w/ CYP3A4 inhibitors eg, itraconazole, ketoconazole, posaconazole, erythromycin, clarithromycin, telithromycin, HIV PIs, nefazodone, danazol, ciclosporin, amiodarone, amlodipine, diltiazem, verapamil, gemfibrozil, other fibrates or statins, niacin (≥1 g daily), fusidic acid, colchicine. Increased plasma exposure w/ grapefruit juice. Enhanced effects of vit K antagonists. Reversible paradoxical HDL-C reduction w/ glitazones. Decreased plasma exposure w/ rifampicin. Monitor w/ CYP2C19-, CYP2A6-, CYP2C9-metabolised drugs.